GSK on Wednesday forecast sales growth to slow in 2026 in the first outlook presented by new CEO Luke Miels as the drugmaker shifts focus on expanding its pipeline to counter looming patent expiries f... ...

Group 1 - Sanofi SA is considered one of the best cheap stocks to buy for 2026 according to Citi Research, which initiated coverage of six large European pharmaceutical stocks including Sanofi [1] - Citi assigned Sanofi a Neutral rating with a price target of €85, indicating concerns about the company's drug development progress and a weakened long-term growth outlook due to pipeline setbacks [2][3] - The current valuation of Sanofi is approximately 10 times expected 2026 earnings, reflecting the setbacks in its pipeline, and the market is unlikely to reward the stock with a higher multiple without tangible evidence of improvement [3] Group 2 - Sanofi reported positive results for its experimental medicine amlitelimab in Phase 3 clinical studies for moderate-to-severe atopic dermatitis, with data coming from two major global trials, SHORE and COAST 2 [4] - The results from the studies indicate that amlitelimab was generally well tolerated, with side effects consistent with previous findings [4] - Sanofi operates in various segments including specialty care, vaccines, and general medicines, focusing on the research, development, manufacturing, and marketing of pharmaceutical products [5]

Group 1 - Wave Life Sciences Ltd. regained full rights to WVE-006 from GSK Plc, allowing the company to advance the program for alpha-1 antitrypsin deficiency (AATD) [1] - AATD is caused by SERPINA1 gene mutations, leading to low levels of the protective protein AAT, which results in severe emphysema/COPD and liver disease [2] - The RestorAATion-2 clinical trial is on track, with data from the 400 mg multidose cohort expected in the first quarter of 2026, and plans for engaging with the FDA for potential accelerated approval [3] Group 2 - GSK selected a fourth program to advance to a development candidate under their collaboration, which allows GSK to advance up to eight programs using Wave's PRISM platform, potentially leading to $2.8 billion in milestone payments for Wave [4] - Wave expects its current cash and cash equivalents to fund operations into the third quarter of 2028 [5] - WVE stock increased by 4.48% to $13.52 as of the last check on Monday [5]

Core Insights - Wave Life Sciences has regained full rights to WVE-006, an investigational RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD), from GSK, allowing the company to advance its development strategy independently [1][2] - The company plans to engage with the FDA regarding a potential accelerated approval pathway for WVE-006, with regulatory feedback expected by mid-2026 [1][2] - Wave anticipates data from the 400 mg multidose cohort of the RestorAATion-2 clinical trial in the first quarter of 2026, with additional data from the 600 mg cohorts expected later in 2026 [1][2] Company Developments - Wave Life Sciences is focused on RNA medicines and has a diversified pipeline that includes clinical programs for AATD, obesity, Duchenne muscular dystrophy, and Huntington's disease [6] - The company has a strong cash runway, expecting to fund operations into the third quarter of 2028, not including potential future milestone payments from its collaboration with GSK [4] - Wave's collaboration with GSK continues to expand, with a fourth program selected for advancement, potentially leading to up to $2.8 billion in milestone payments and tiered royalties [3] Clinical Trial Progress - WVE-006 has shown promising interim data, achieving key treatment goals for AATD, including significant AAT production during acute phase response [2] - The ongoing RestorAATion-2 clinical trial is on track, with data from the 400 mg cohort expected in early 2026 and further data from the 600 mg cohort anticipated later that year [1][2]

Group 1: Federal Reserve and Kevin Walsh - Kevin Walsh has been confirmed as Trump's pick for Fed chair, known for his criticism of the central bank and calls for a reduction in its balance sheet [1] - Walsh is expected to be well-received by policymakers due to his previous experience as a Fed governor and his persuasive arguments [2] - The announcement of Walsh's appointment has been a catalyst for market reactions, with expectations of a stable Fed independence [9][10] Group 2: Market Reactions and Economic Indicators - Treasuries have remained steady despite volatility in other asset classes, with the 10-year yield at 4.218% [3] - The dollar experienced its largest rally since May, gaining approximately 210% over the past week, indicating challenges to US exceptionalism [4] - Bitcoin fell below $80,000 for the first time since April, reflecting a broader pullback from riskier assets amid a global sell-off [5] Group 3: Earnings Season and Market Expectations - Over 100 S&P 500 companies, including major firms like Amazon and Alphabet, are set to report earnings this week, with expectations of better-than-expected results [14][15] - In the US, earnings revisions are outpacing those in Europe, with consensus expectations for seven of the eleven S&P sectors to show sequential declines despite strong overall performance [17] - The stronger euro is impacting European multinationals, but expectations have already been adjusted, suggesting limited downside surprises [19] Group 4: Emerging Markets and Asia - Emerging market equities and rates are viewed positively, with expectations of reduced volatility benefiting high beta assets [22] - Asian markets, particularly Korea, have seen significant gains despite recent pullbacks, indicating a normalization after a period of frenzy [23] - The weaker dollar is expected to support a favorable earning setup for Asian equities and emerging markets overall [24]

Core Insights - AstraZeneca is set to list on the New York Stock Exchange, aiming to strengthen its investment presence in the U.S., its largest market [1][10] - The company is making significant investments in China, including a $15 billion commitment through 2030, to enhance manufacturing and R&D capabilities [4][10] - AstraZeneca's strategy reflects a broader trend in the pharma industry, where companies are increasingly looking to China for innovation as patents on blockbuster drugs expire [2][3] Investment and Partnerships - AstraZeneca's investment in China will cover the entire value chain from drug discovery to manufacturing, highlighting its commitment to Chinese innovation [5] - The company has partnered with Hong Kong-listed CSPC Pharmaceuticals to bolster its obesity portfolio, involving an upfront payment of $1.2 billion and potential additional payments of $17.3 billion based on milestones [6][7] - This partnership is part of a growing trend of licensing deals between Big Pharma and Chinese biotechs, with 57 such deals reported in 2025 [14] Market Dynamics - The U.S. market presents pricing challenges that are pressuring Big Pharma, making the Chinese market increasingly important for revenue and research [2][3][10] - AstraZeneca's commitment to China is underscored by its recent actions, despite facing regulatory scrutiny in the past [12][13] - The Chinese biopharma sector is evolving rapidly, with a focus on next-generation therapeutics and efficient clinical trial processes, positioning it as a potential leader in biotechnology [15][16]

Group 1 - Sanofi reported adjusted earnings of 91 cents per share on $13.5 billion in fourth-quarter sales, exceeding analysts' expectations of 84 cents per share and $13.57 billion in sales [1][1][1] - The company's earnings per share increased from 68 cents in the same period last year, while sales rose from $11.89 billion [1][1][1] Group 2 - Sanofi's stock experienced a slight increase following the earnings report, indicating a positive market reaction to the results [1][1][1]

Core Viewpoint - Companies that rely on a single dividend and lack core technology will ultimately struggle to sustain themselves in the long run [4][30]. Group 1: Company Overview - Zhifei Biological, once a leading vaccine company in China, is facing a significant downturn, with projected net losses of 10.698 billion to 13.726 billion yuan for 2025, marking a year-on-year decline of 630% to 780% [5][6]. - The company’s revenue skyrocketed from 4 billion yuan in 2016 to 52.92 billion yuan in 2023, with net profits reaching 7.915 billion yuan, showcasing a rapid growth trajectory [12]. - However, the company’s reliance on agency business has proven to be a fragile foundation, leading to a severe profit crisis as market dynamics shifted [13][15]. Group 2: Financial Crisis - By 2025, Zhifei Biological's revenue is expected to plummet to 26.07 billion yuan, with a net profit of only 1.991 billion yuan, reflecting a nearly 75% year-on-year decline [14]. - The company is experiencing a liquidity crisis, with total liabilities of 16.786 billion yuan and a significant short-term debt of 10.318 billion yuan, while cash reserves are only 2.498 billion yuan, resulting in a funding gap exceeding 7.8 billion yuan [18][20]. - To alleviate inventory pressure, Zhifei Biological has initiated promotional activities and is attempting to optimize its debt structure through bond issuance, but the process has faced obstacles due to unexpected losses [19][20]. Group 3: Wealth and Market Dynamics - The wealth of the Jiang Rensheng family has drastically decreased from 140 billion yuan in 2021 to 42 billion yuan in 2025, a loss equivalent to the combined market value of two leading listed companies in Chongqing [17]. - The stock price of Zhifei Biological has also dropped from 360 billion yuan to 41 billion yuan, reflecting the company's declining market position [18]. - The rise of Zhang Xinghai and Yan Min, who have transitioned to become the new wealth leaders in Chongqing through advancements in the smart automotive sector, highlights a shift in the local business landscape [24][28]. Group 4: Industry Trends - The challenges faced by Zhifei Biological are indicative of a broader trend in the vaccine industry, where domestic companies are increasingly breaking the monopoly of foreign firms, leading to intensified competition [30]. - The shift from reliance on agency business to a focus on independent innovation is becoming essential for survival in the evolving market [31][32].

Core Insights - Pfizer Inc. is exiting its HIV-focused joint venture, ViiV Healthcare, with a transaction valued at approximately $1.9 billion [2][3] - Shionogi will increase its stake in ViiV Healthcare from 10% to 21.7% by paying $2.13 billion for newly issued shares, while GSK retains a majority stake of 78.3% [3] - Pfizer will receive $1.88 billion for its 11.7% holding in ViiV Healthcare, and GSK will receive a $250 million special dividend as part of the deal [3] - The transaction is subject to regulatory approvals and is expected to close in the first quarter of 2026 [4] - Pfizer anticipates a challenging period ahead, with expectations of no revenue growth until 2029 due to declining sales of its COVID vaccine and treatment, price cuts, and loss of patent protection on key drugs [4] - Pfizer's CEO indicated preparations for a consumer-driven obesity drug market, which could rival the success of Viagra, despite not expecting rapid growth in the cash-pay obesity market [5][6]

在这一年的交易热潮中，跨国巨头们的采购风格各有不同。谁出手频次最高？谁手笔最大？经济观 察报分析了全年150多笔交易，复盘跨国药企的投资画像与交易特色。 多位受访者对经济观察报表示，其所在药企与潜在合作方达成了进一步沟通意向，他们判断2026 年中国创新药对外授权交易热仍会持续。 2025年爆发式增长的对外授权交易验证了中国创新药资产的价值，该年对外授权总交易额超1300 亿美元，交易数超150笔（约占全球40%），创下历史新高。 阿斯利康最活跃 在交易频次上，阿斯利康是最活跃的跨国药企，2025年一共出手了5次。 合作方包括石药集团（01093.HK）、和铂医药（02142.HK）、加科思药业（01167.HK）、元 思生肽等。其中，在2025年6月与石药集团达成的潜在总交易额超53亿美元的合作，可排进年度 交易额前四。在资产选择上，阿斯利康主要集中在临床早期管线，以及技术平台合作。 在交易频次上，阿斯利康是最活跃的跨国药企，2025年一共 出手了5次。从立即兑现的首付款看，辉瑞与武田制药出手最 阔绰。 作者：张英 封图：图虫创意 作为中国市场销售额最高的外资药企，在经历2024年的公司治理风暴后，阿斯利康 ...